Brief: Nicox Says First Patient Screened In China For Denali Trial

Ocumension Therapeutics

16/12/2021 07:10

Dec 16 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX ANNOUNCES FIRST PATIENT IN CHINA SCREENED IN THE
ONGOING
NCX 470 DENALI PHASE 3 TRIAL IN GLAUCOMA
    * DENALI PHASE 3 CO-FUNDED EQUALLY BY NICOX AND OCUMENSION
THERAPEUTICS
    * RESULTS FROM DENALI ARE EXPECTED BY END OF 2023
    * DENALI TRIAL WAS DESIGNED TO FULFILL THE REGULATORY
REQUIREMENTS
TO SUPPORT NDA SUBMISSIONS OF NCX 470 IN THE U.S. AND CHINA
    * NCX 470 IS ALSO BEING EVALUATED IN MONT BLANC PHASE 3
CLINICAL
TRIAL, WITH ITS RESULTS EXPECTED IN Q1 2023

Source text for Eikon:  ID:nGNX9t9kGS 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))